Intelligence · Decide
Decision-grade intelligence across global cannabis.
€1,420 a year, everything included · self-serve, billed annually
What is Decide
The whole cannabis market, in one place — and already connected.
Every piece is somewhere. None of it is connected, and you are the one stitching it together.
One analyst-curated graph.
- ✓Every market and every company, on one platform
- ✓Filings standardised, with the source one click away
- ✓Regulation tracked as it develops, tied to the market it affects
- ✓News classified as it lands, linked to the company it touches
- ✓The context is already built when you arrive
The connected graph
One graph, twelve connected modules, one subscription.
Assess any target market end to end: regulation, demand, supply and competition, on one page.
One page per company, with its financials, news, deals, trials and licences already joined up.
- RegulatoryExilby authorised in Germany9 Jun 2026
- Clinical trialsExilby · chronic painApproved
- CountriesGermany, Europe’s largest medical marketLinked
- Datapacks“Cannabinoids come of age”Analyst read
Updates as situations develop, scored for momentum so you see what is at stake per market.
Vetted sources only, classified as they land and linked to the company, market and deal they touch.
- Vireo Growth closes a US$60m real-estate loanM&A
- Johns Hopkins starts a Phase II of Epidiolex in Sturge-Weber syndromeTrials
- AYR Wellness hands its Ohio operations to its noteholdersM&A
- IM Cannabis sells its European arm, including AdjupharmM&A
- PleoPharma’s PP-01 cuts cannabis-withdrawal severity in a Phase 1b/2aTrials
Cleaned, structured datasets from official and aggregated sources, cutting across countries and companies.
Standardised for currency, units and definitions, with private-company signals beside the listed names.
Normalised to USD and source-linked, with the consideration split and multiples where they are disclosed.
The funds, strategics and lenders behind the deals, linked to their portfolio companies.
Investigational products by indication and mechanism, connected to the company and the trial behind them.
Find evidence by condition, substance and population, with every trial matched to its sponsor and product.
Topic-level analysis built by our analysts, with the so-what already worked out and the data attached.
- UK medical cannabis: potency keeps rising as its price premium narrows
- Denmark’s medical cannabis pilot ends on a record 22,410 prescriptions
- Spain ships tens of tonnes of cannabis abroad, yet its patients can only reach two products
The full monthly brief, webinars as analysed transcripts and podcasts, with the underlying data attached.
- The full country-by-country brief, every edition since August 2023
- countries covered in each edition
- Full transcripts, already analysed, not just recordings
- The datasets behind every piece, one click away
Six slices of Decide, open for you to explore before you subscribe.
Pick a market or a tracker to see where it stands today. Every chart is drawn from the records you get in Decide, and each tab opens the full showcase page behind it.
England dispensed 1.77m items of medical cannabis in 2025, and no single supplier controls the shelf any more.
NHSBSA dispensing records (England only, a floor for the UK), Home Office import licensing, dated formulary snapshots and SimilarWeb clinic traffic. From our UK Medical Cannabis Market Report, September 2026. Read 8 Oct 2026.
Germany imported 205 tonnes in 2025, then posted its first quarterly decline on record.
BfArM quarterly import releases, GKV-Gamsi reimbursement, Cannamonitor retail price reconciliation and patient projections, SimilarWeb telemedicine traffic and our German regulatory tracker. Read 8 Oct 2026.
Spain grows medical cannabis for export, and at home only hospital pharmacies may dispense it.
- Oct 2025Decree published: hospital pharmacies only
- Jan 2026Monograph: oral solutions only, no flower
- Jan 2026Laboratory register opens
- Mar 2026Two laboratories registered
UK Home Office and BfArM records of arrivals from Spain, AEMPS / INCB production and trade, the AEMPS cultivation register, CGCOF pharmacy census, OEDA surveys and seizure analysis, and RD 903/2025. Read 8 Oct 2026.
Australia imported a record 81 tonnes in 2025, while units supplied to patients fell 28.6% in a single half.
ODC import and production records, TGA sponsor supply returns (units supplied, not patients), Statistics Canada declared export values and SimilarWeb clinic traffic, May 2026. Read 8 Oct 2026.
2026 has already logged more cannabis deals than all of 2025, with a quarter still to run.
- Vireo Growth closes a US$60m real-estate loanUSDebt
- AYR Wellness hands its Ohio operations to its noteholdersUSAsset sale
- Griffin bids for bankrupt grow-supply distributor BFG SupplyUSAsset sale
- IM Cannabis sells its European arm, including AdjupharmIL · DEAsset sale
Every cannabis deal in our M&A and funding tracker, each linked to its source. Tags exceed deals because one deal can carry several markets or layers. Read 8 Oct 2026.
Cannabinoid trial starts hit a record in 2025, yet only 16% of the pipeline is Phase III or IV.
One record per trial, merged from 13 registries and deduplicated. Funder and country splits come from the 24 Aug 2026 analysis; everything else is today’s count. Read 8 Oct 2026.
In Decide the same view exists for every market we cover, connected to the companies, deals and trials inside it.Get the whole graph for €1,420 a year →
See it work
Follow one decision, end to end.
What changed, and where?
A new cannabinoid medicine is authorised in Europe’s largest medical market, and the record sits inside Germany’s regulatory picture rather than on its own.
- RegulatoryExilby authorised in Germany9 Jun 2026
- Clinical trialsExilby · chronic painApproved
- DatapacksThe clinical-trial pipeline behind Exilby10 Jun 2026
Who is behind it, and what else are they doing?
The developer’s profile already links the authorisation, its trial and the analysis, so you see the pipeline and not just the press release.
How big is the market it lands in?
Imports grew to 205 tonnes in 2025, then fell for the first time, while the retail price kept dropping. That is the market a new product launches into.
Through which channel do patients actually get it?
8.14M monthly visits across 42 tracked platforms, with one of them drawing 39% of the traffic. That tells you who to partner with to reach prescribers.
So what does it mean for me?
The datapack puts the authorisation in the context of the trial pipeline behind it, so operators and investors see what it changes for them.
What changed, and where?
A new cannabinoid medicine is authorised in Europe’s largest medical market, and the record sits inside Germany’s regulatory picture rather than on its own.
- RegulatoryExilby authorised in Germany9 Jun 2026
- ProductsExilby (VER-01) · full-spectrum oral extractLaunched Sep 2026
- Clinical trialsVER-01 · chronic low back painPhase III
- DatapacksThe clinical-trial pipeline behind Exilby10 Jun 2026
Who is behind it, and what else are they doing?
The developer’s profile already links the authorisation, its trial and the analysis, so you see the pipeline and not just the press release.
What changesThe BStabG (passed 10 Jul 2026) makes extracts, isolates and dronabinol a second-line option after a six-month trial of an approved finished medicine, expected from 2027.
Which market does it land in, and who pays for it?
Exilby is an oral extract, so its market is not flower. Statutory insurers paid €80M for extracts and isolates in 2025 and €44.1M for approved finished medicines, a slice that shrank 10%. The law passed in July pushes reimbursed patients the other way: from 2027, extracts are only paid for after six months on an approved medicine first.
How strong is the evidence, and what comes next?
Exilby won on a Phase III package of more than 1,200 patients, including a head-to-head study against opioids, which is the late-phase depth most of the cannabinoid pipeline still lacks. The US programme decides whether it travels.
Analyst datapack · 10 June 2026Cannabinoids come of age: the clinical-trial pipeline behind Vertanical’s ExilbyThe first high-THC, full-spectrum botanical ever to win pharmaceutical marketing authorisation is the leading edge of a cannabinoid pipeline that has tripled in a decade.
So what does it mean for me?
The datapack sets the approval against the pipeline behind it: large, young and pivoting hard towards whole-plant THC for pain, which is exactly where Exilby sits.
Who uses Decide
Three jobs teams hire Decide to do.
For investors, corporate development, CEOs and boards
For business development, partnerships and international teams
For operations, procurement and regulatory affairs
Decision-grade
The headline is not the decision.
Australia imports a record 81 tonnes of medical cannabis
!True, and not the whole story.
More product is arriving while fewer units reach patients, so stock is building up. If you export to Australia, plan for price pressure: Canada already cut its Australian price 41% in a year.
Read the analysis: Australia Imports a Record 81 Tonnes as Its Medical Cannabis Market Contracts for the First Time →Canadian flower exports surge 67% to C$217M
!True, and not the whole story.
Volume is up and margin is down, and one buyer carries most of the revenue. A German policy change now moves Canadian income directly, so anyone selling Canadian flower should price that risk in.
England dispenses 1.77m items of medical cannabis, up 165%
!True, and not the whole story.
The growth is real, but the shelf has fragmented: no single supplier controls it any more. A new entrant competes on formulary placement and price, not against one incumbent.
Read the analysis: UK medical cannabis: potency keeps rising as its price premium narrows →Spain legalises medical cannabis
!True, and not the whole story.
- Oct 2025Decree published: hospital pharmacies only
- Jan 2026Monograph: oral solutions only, no flower
- Jan 2026Laboratory register opens
- Mar 2026Two laboratories registered
What opened is a hospital-only market for standardised oral preparations, with no flower. If you planned to sell into Spanish pharmacies there is no channel yet; the opportunity today is cultivation and export, which reached 8.2 t to the UK and Germany in 2025.
Read the analysis: Spain ships tens of tonnes of cannabis abroad, yet its patients can only reach two products →This is what you get when someone has already worked out what a number counts, and what it leaves out.
How we build it
We don’t aggregate information. We curate evidence, impose structure, preserve history and add context.
Most cannabis intelligence starts with headlines. We start with evidence.
- Filings, regulatory documents, customs data and official statistics come first.
- Every claim is traced to its origin, not to someone’s interpretation of it.
- The documents are kept, so you can check our conclusions yourself.
Fragmented information becomes decision-ready knowledge.
- Cannabis-specific ontologies for companies, products, licences and markets.
- One framework, so figures compare across jurisdictions and years.
- Related entities and events are connected, so nothing is read in isolation.
Markets move through sequences, not isolated events.
- Developments are tracked over time, never treated as standalone news.
- Change histories make trends and strategic direction visible.
- You see what changed, what held, and why it matters.
A number only means something in context.
- Each development is tied to the market, regulatory and competitive picture.
- Materiality and likely impact separate the signal from the noise.
- We explain why it matters to investors, operators and strategists.
Proof
Coverage that compounds every week.
Objections
Common questions.
AI runs through our own pipeline — ingestion, classification, translation, first-pass extraction — and we would be worse at this without it. What a model cannot do is decide what is worth tracking, how a market should be defined, or which source wins when two disagree. That frame is built before any model runs, and it is why every figure in Decide names its source and reconciles to one schema. You get the finished picture instead of an afternoon of checking.
News says a thing happened. Decide connects it to the company, country, filing and trial — and tells you what it means. A graph, not a feed.
Standardised units and currencies, contradictions reconciled (not averaged away), the original source one click away, and analyst context on what it means.
Updated continuously, with change logs showing what moved and when — new datasets, dashboards, company profiles and news stories land every week, and the log shows each one.
Essentials keeps one professional on top of one market, every month. Decide gives a team every market and every company, cross-linked, with the deals, trials and financials behind them.
About €118 a month, or under €4 a day, for decision-grade intelligence. One avoided mistake, one faster diligence or one sharper board pack pays for the year — and Decide replaces several single-purpose subscriptions plus the analyst hours spent stitching them together, for less than the cost of an afternoon’s research.
125+ countries, deepest in internationally exposed demand markets such as Canada, Germany, the UK and Australia. If your market is light, tell us — coverage expands every week.
Pricing